Skip to main content
永顺生物 logo

永顺生物 — Investor Relations & Filings

Ticker · 920729 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2025-08-25 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920729

About 永顺生物

https://www.winsun-gd.com/

Guangdong Winsun Bio-Pharmaceutical Co., Ltd. is a specialized enterprise focused on the research, development, production, and distribution of veterinary biological products. The company primarily develops vaccines for livestock and poultry, with a significant emphasis on swine and avian health. Its product portfolio includes live and inactivated vaccines targeting major diseases such as classical swine fever, porcine reproductive and respiratory syndrome (PRRS), and avian influenza. Winsun Bio-Pharmaceutical leverages advanced biotechnology to provide comprehensive animal disease prevention and control solutions. The company maintains a strong focus on technological innovation and quality management, operating multiple GMP-certified production lines to ensure the efficacy and safety of its biological preparations. Its research initiatives often involve collaborations with academic institutions to advance veterinary medicine and support the animal husbandry sector.

Recent filings

Filing Released Lang Actions
拟续聘会计师事务所公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an accounting firm (auditor) for the 2025 fiscal year. It details the auditor's background, qualifications, past performance, and the board and audit committee's approval process. There are no actual financial statements or audit reports included, nor is there a detailed audit opinion or results. The document is relatively short (3050 characters) and serves as a formal notice of the intention to rehire the auditor, pending shareholder approval. This fits the category of a Regulatory Filing (RNS) because it is an official announcement related to audit arrangements but does not contain the audit report itself or detailed financial data.
2025-08-25 Chinese
2024 年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is titled as an announcement regarding the implementation of the 2024 annual equity distribution (dividend) plan by Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the dividend amount, payment dates, tax withholding policies, and the record and ex-dividend dates. The document is short (1265 characters) and focuses on dividend distribution specifics rather than presenting financial statements or comprehensive financial performance. It also references the shareholders' meeting resolution approving the dividend plan. This matches the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders.
2025-05-29 Chinese
2024 年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a 2024 Annual General Meeting (AGM) resolution announcement for Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results on various proposals including the 2024 annual report, financial statements, budget, dividend distribution plan, credit applications, and board member appointments. The document primarily reports the outcomes of shareholder votes at the AGM. It does not contain the full annual report or financial statements themselves but rather the resolutions passed at the meeting. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is over 6000 characters, indicating it is not a brief notice but a detailed voting result announcement. Hence, the classification is DVA with high confidence.
2025-05-25 Chinese
关于补选第五届董事会审计委员会和战略委员会委员的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the replacement of members on the company's board committees, specifically the audit committee and strategic committee. It details the resignation of a director and the election of a new member to these committees. The content focuses on board/management changes and committee composition, with no financial data or report attached. The document is short (964 characters) and is clearly a formal announcement about board committee membership changes, fitting the category of Board/Management Information (MANG).
2025-05-25 Chinese
第五届董事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 10th meeting of the 5th Board of Directors of Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the meeting date, attendance, agenda, and voting results related to the election of new board committee members. There is no financial data, earnings information, or report publication mentioned. The content focuses on board decisions and changes in board committee composition, which fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or a certification. Therefore, the appropriate classification is MANG with high confidence.
2025-05-25 Chinese
广东君信经纶君厚律师事务所关于广东永顺生物制药股份有限公司2024年年度股东会的法律意见书
Regulatory Filings
2025-05-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.